Increased time spent on discussing testing for colorectal cancer (CRC) was associated with patient satisfaction in older adults. Adults aged 76 to 85 years were more likely to continue testing for ...

ACG posed several key questions and developed practical recommendations for practice providers. The recommendations were crafted through a focused literature search and supplemented by existing ...

Multigene panel testing should be considered for all patients with colorectal cancer (CRC) who are diagnosed younger than age 50 years, new findings suggest. Among 450 patients with early-onset CRC, ...

Please provide your email address to receive an email when new articles are posted on . At 12 months, 39% of those in the intervention group and 29% in the comparator group completed CRC screening.

WASHINGTON -- A blood-based test for the early detection of colorectal cancer (CRC) met its prespecified sensitivity and specificity endpoints, according to results from the PREEMPT CRC study. Using ...

Dr Kristen Ciombor discusses utilization of biomarkers and molecular testing in the treatment of patients with CRC. Kristen Ciombor, MD: In terms of molecular testing for colorectal cancer, in early ...

Although considered a single class, fecal immunochemical tests (FITs) vary in their ability to detect advanced colorectal neoplasia (ACN) and should not be considered interchangeable, new research ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Multimodal circulating tumor DNA blood-based colorectal cancer screening tests may have clinically ...

New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening options, a cost-effectiveness modeling study suggested. In a comparison against ...

Mark Stenhouse left his executive role at AbbVie to join Exact Sciences because he felt the company was fighting a worthy battle: preventing colorectal cancer. Mr. Stenhouse, now Exact Science’s ...

MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most ...